AU2022269348A1 - Pkc-theta modulators - Google Patents

Pkc-theta modulators Download PDF

Info

Publication number
AU2022269348A1
AU2022269348A1 AU2022269348A AU2022269348A AU2022269348A1 AU 2022269348 A1 AU2022269348 A1 AU 2022269348A1 AU 2022269348 A AU2022269348 A AU 2022269348A AU 2022269348 A AU2022269348 A AU 2022269348A AU 2022269348 A1 AU2022269348 A1 AU 2022269348A1
Authority
AU
Australia
Prior art keywords
group
alkyl
hydrogen
mmol
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022269348A
Other languages
English (en)
Inventor
Jeremy Besnard
Anthony Bradley
Jérôme MENEYROL
Peter Ray
Simon Richards
Catarina SANTOS
Virginie SUCHAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2022269348A1 publication Critical patent/AU2022269348A1/en
Assigned to CELGENE CORPORATION reassignment CELGENE CORPORATION Request for Assignment Assignors: EXSCIENTIA AI LIMITED
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022269348A 2021-05-06 2022-05-06 Pkc-theta modulators Pending AU2022269348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106486.0 2021-05-06
GB202106486 2021-05-06
PCT/GB2022/051167 WO2022234299A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Publications (1)

Publication Number Publication Date
AU2022269348A1 true AU2022269348A1 (en) 2023-10-26

Family

ID=82100804

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022269348A Pending AU2022269348A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Country Status (14)

Country Link
US (1) US20240239794A1 (https=)
EP (1) EP4334316A1 (https=)
JP (1) JP2024518447A (https=)
KR (1) KR20240024063A (https=)
CN (1) CN117295738A (https=)
AU (1) AU2022269348A1 (https=)
BR (1) BR112023022883A2 (https=)
CA (1) CA3214088A1 (https=)
CL (1) CL2023003247A1 (https=)
CO (1) CO2023015005A2 (https=)
IL (1) IL307669A (https=)
MX (1) MX2023013012A (https=)
PE (1) PE20250019A1 (https=)
WO (1) WO2022234299A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
CN118772140B (zh) * 2023-04-07 2026-04-17 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途
WO2025255294A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use
WO2025255298A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924762A (en) * 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
US9556126B2 (en) 2013-12-20 2017-01-31 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
AU2020284742B2 (en) * 2019-05-28 2026-03-05 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators

Also Published As

Publication number Publication date
IL307669A (en) 2023-12-01
KR20240024063A (ko) 2024-02-23
CA3214088A1 (en) 2022-11-10
WO2022234299A1 (en) 2022-11-10
CN117295738A (zh) 2023-12-26
MX2023013012A (es) 2024-03-25
CL2023003247A1 (es) 2024-04-26
BR112023022883A2 (pt) 2024-01-23
US20240239794A1 (en) 2024-07-18
CO2023015005A2 (es) 2024-02-05
JP2024518447A (ja) 2024-05-01
EP4334316A1 (en) 2024-03-13
PE20250019A1 (es) 2025-01-07

Similar Documents

Publication Publication Date Title
JP6775645B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
TWI902789B (zh) 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法
CN114127067B (zh) 作为hpk1抑制剂的三环化合物及其用途
TWI789381B (zh) 雜環化合物
AU2022269348A1 (en) Pkc-theta modulators
TW202012415A (zh) 化學化合物
TW201938561A (zh) 化學化合物
KR20260010430A (ko) Kras g12s 및 g12c 억제제
TW202039483A (zh) 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途
TW202116773A (zh) 作為ＨＰＫ１抑制劑之吡咯并［２，３－ｂ］吡及其用途
TW202115025A (zh) 作為hpk1抑制劑之胺基吡化合物及其用途
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
EP3481828A1 (en) Spiro-fused cyclic ureas as inhibitors of rock
WO2022234298A1 (en) Pkc-theta modulators
TW202140478A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶（btk）及其使用方法
CN116528857A (zh) Malt-1调节剂
MX2014003800A (es) Derivado de pirazoloquinolina.
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
EP3458460A1 (en) Imidazoles as histone demethylase inhibitors
KR20230079059A (ko) Hpk1 저해제로서의 3-[(1h-피라졸-4-일)옥시]피라진-2-아민 화합물 및 이의 용도
TW202438054A (zh) 作為ＭＴＡ－協同ＰＲＭＴ５抑制劑的５－胺基－６，８－二氫－１Ｈ－呋喃并［３，４－ｄ］吡咯并［３，２－ｂ］吡啶－２－甲醯胺衍生物
CN121057733A (zh) 吡啶并咪唑酮化合物、其制备及其治疗用途
EA046667B1 (ru) ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ
CN121464138A (zh) Mllt1和/或mllt3的protac降解剂
TW202608884A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶（btk）及其使用方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELGENE CORPORATION

Free format text: FORMER APPLICANT(S): EXSCIENTIA AI LIMITED